About Sayan Mondal
Form D filings for NeuroLambda Therapeutics in 2024 list Sayan Mondal as president and director.
Sayan Mondal first appears on SEC filings in 2024.
Experience
This experience comes from SEC filings. The years are when the filings name Sayan Mondal in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Sayan Mondal works with at each company, as listed on that company's latest Form D.
NeuroLambda Therapeutics, Inc. · Form D, Jul 17, 2024
BK
Byungchan Kim
Director
XJ
Xiaowei Jin
Director